<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283049</url>
  </required_header>
  <id_info>
    <org_study_id>HOE901_4052</org_study_id>
    <nct_id>NCT00283049</nct_id>
  </id_info>
  <brief_title>Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control</brief_title>
  <official_title>Safety and Efficacy of Insulin Glargine Injection [rDNA Origin] Treatment in Place of the TZD or the Sulfonylurea or Metformin in Triple Agent Therapy for T2DM Adult Subjects With Unsatisfactory Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the change in hemoglobin A1c (HbA1c) from baseline to
      Week 12 between the 3 treatment arms.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to technical issues relating to the Electronic diary data.
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin A1c (HbA1c) From Baseline to Week 12</measure>
    <time_frame>12 weeks from Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Individual Time Points in HbA1c, Insulin Doses, and Total Insulin Dosage</measure>
    <time_frame>60 weeks from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving an HbA1C Less Than (&lt;) 7.0% and Less Than (&lt;) 6.5%</measure>
    <time_frame>60 weeks from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Study Time Points in 7-point Blood Glucose (BG) Profile (Before Meals, 2 Hours After Meals, at Bedtime)</measure>
    <time_frame>60 weeks from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Study and to Individual Time Points in Components of Lipid Profile (Total Cholesterol, High-density Lipoprotein Cholesterol [HDL], Low-density Lipoprotein Cholesterol [LDL], Triglycerides, LDL Subfractions)</measure>
    <time_frame>60 weeks from Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia, and Serious Hypoglycemia</measure>
    <time_frame>60 weeks from Baseline</time_frame>
    <description>Symptomatic hypoglycemia (BG&lt;70 mg/dL, BG&lt;50 mg/dL): including 1 or more symptoms: headache, dizziness, general feeling of weakness, drowsiness, confusion, pallor, irritability, trembling, sweating, rapid heartbeat &amp; a cold, clammy feeling.
Mild-to-moderate hypoglycemia: SMBG ≥ 36 mg/dL but &lt;70 mg/dL
Severe hypoglycemia: assistance of another party is required &amp; either:
SMBG of &lt;36 mg/dL, or
with prompt response to treatment with oral carbohydrates, IV glucose or glucagon.
Serious hypoglycemia:
Hypoglycemia with coma/loss of consciousness Or Hypoglycemia seizure/convulsion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia and Serious Hypoglycemia</measure>
    <time_frame>60 Weeks from Baseline</time_frame>
    <description>Symptomatic hypoglycemia (BG&lt;70 mg/dL, BG&lt;50 mg/dL): including 1 or more symptoms: headache, dizziness, general feeling of weakness, drowsiness, confusion, pallor, irritability, trembling, sweating, rapid heartbeat &amp; a cold, clammy feeling.
Mild-to-moderate hypoglycemia: SMBG ≥ 36 mg/dL but &lt;70 mg/dL
Severe hypoglycemia: assistance of another party is required &amp; either:
SMBG of &lt;36 mg/dL, or
with prompt response to treatment with oral carbohydrates, IV glucose or glucagon.
Serious hypoglycemia:
Hypoglycemia with coma/loss of consciousness Or Hypoglycemia seizure/convulsion.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulins + Sulfonylurea (SU) + Thiazolidinedione (TZD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: Insulin glargine administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulins + Metformin (MET) + Thiazolidinedione (TZD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2: Insulin glargine administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulins + Metformin (MET) + Sulfonylurea (SU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 3: Insulin glargine administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added arms after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Insulin glargine administered subcutaneously once daily.</description>
    <arm_group_label>Insulins + Sulfonylurea (SU) + Thiazolidinedione (TZD)</arm_group_label>
    <arm_group_label>Insulins + Metformin (MET) + Thiazolidinedione (TZD)</arm_group_label>
    <arm_group_label>Insulins + Metformin (MET) + Sulfonylurea (SU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
    <arm_group_label>Insulins + Sulfonylurea (SU) + Thiazolidinedione (TZD)</arm_group_label>
    <arm_group_label>Insulins + Metformin (MET) + Thiazolidinedione (TZD)</arm_group_label>
    <arm_group_label>Insulins + Metformin (MET) + Sulfonylurea (SU)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects meeting all of the following criteria will be considered for enrollment into the
        study:

          1. 18 to 79 years of age, inclusive

          2. Diagnosis of type 2 diabetes mellitus

          3. Continuous treatment with therapeutic dosages of a thiazolidinedione (rosiglitazone or
             pioglitazone), metformin, and a sulfonylurea daily prior to entering the study

          4. Screening HbA1c ≥ 7.0%

          5. Fasting C-peptide concentration ≥ 0.27 ng/ml

          6. Negative glutamic acid decarboxylase (GAD) antibodies

          7. Demonstrated ability and willingness to perform self-monitoring blood glucose (SMBG)
             using a plasma-referenced glucose meter and to maintain an electronic diary

          8. Demonstrated ability and willingness to use an electronic diary to record SMBG
             results, insulin doses, and hypoglycemic events.

          9. Signed, informed consent and Health Insurance Portability and Accountability Act
             (HIPAA) documentation

        Exclusion Criteria:

          1. Stroke, myocardial infarction, coronary artery bypass graft, percutaneous transluminal
             coronary angioplasty, or angina pectoris, within the last 12 months

          2. Cardiac status New York Heart Association (NYHA) III-IV

          3. Impaired renal function as shown by, but not limited to, serum creatinine ≥ 1.5 mg/dL
             for males, or ≥ 1.4 mg/dL for females

          4. Chronic use of insulin: (more than 3 weeks of continuous use) in the past 12 months

          5. Acute infection

          6. Clinically significant peripheral edema

          7. Acute or chronic history of metabolic acidosis, including diabetic ketoacidosis

          8. Clinical evidence of active liver disease, or serum alanine aminotransferase (ALT) or
             aspartate aminotransferase (AST) 2.5 times the upper limit of the normal range

          9. History of hypoglycemia unawareness

         10. Pregnancy or lactation

         11. Known hypersensitivity to insulin glargine or any of the components of Lantus®

         12. Known hypersensitivity to insulin glulisine or any of the components of Apidra®

         13. Any malignancy within the last 5 years, with the exception of adequately treated basal
             or squamous cell carcinoma of the skin or adequately treated cervical carcinoma in
             situ

         14. Current addiction or current alcohol abuse, or history of substance or alcohol abuse
             within the last 2 years

         15. Diagnosis of dementia

         16. Subject is the investigator or any sub-investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the protocol

         17. Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study. Subject unlikely to comply with protocol, e.g.,
             uncooperative attitude, inability to return for follow-up visits, and unlikelihood of
             completing the study

         18. subject is currently taking or was treated with the following medications 3 months
             prior to screening: Byetta(exenatide), Starlix(nateglinide),Prandin (repaglinide),
             Januvia(sitagliptin), Janumet(metformin + sitagliptin)

         19. Any disease or condition that in the opinion of the investigator and/or sponsor may
             interfere with the completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Jean-Louis</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>sanofi-aventis, US</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2006</study_first_submitted>
  <study_first_submitted_qc>January 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <results_first_submitted>December 16, 2009</results_first_submitted>
  <results_first_submitted_qc>January 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 19, 2010</results_first_posted>
  <last_update_submitted>January 7, 2011</last_update_submitted>
  <last_update_submitted_qc>January 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>2,4-thiazolidinedione</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Insulin Glargine + Sulfonylurea (SU) + Thiazolidinedione (TZD)</title>
          <description>Arm 1: Insulin glargine (IG) administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
        </group>
        <group group_id="P2">
          <title>Insulin Glargine + Metformin (MET) + Thiazolidinedione (TZD)</title>
          <description>Arm 2: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
        </group>
        <group group_id="P3">
          <title>Insulin Glargine + Metformin (MET) + Sulfonylurea (SU)</title>
          <description>Arm 3: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128">2 randomized patients did not receive study drug and were not included in the safety population</participants>
                <participants group_id="P2" count="128">1 randomized patient did not receive study drug and was not included in the safety population</participants>
                <participants group_id="P3" count="130">1 randomized patient did not receive study drug and was not included in the safety population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation of Study</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer requires study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SU + TZD + IG</title>
          <description>Arm 1: Insulin glargine(IG) administered subcutaneously once daily plus a sulfonylurea and a thiazolidinedione(TZD). Insulin glulisine will be added after Week 12 or later for those subjects needing additional prandial insulin therapy (HbA1c &gt;6.5%)</description>
        </group>
        <group group_id="B2">
          <title>MET + TZD + IG</title>
          <description>Arm 2: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a thiazolidinedione (TZD). Insulin glulisine will be added after Week 12 or later for those subjects needing additional prandial insulin therapy (HbA1c &gt;6.5%)</description>
        </group>
        <group group_id="B3">
          <title>MET+SU + IG</title>
          <description>Arm 3: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added after Week 12 or later for those subjects needing additional prandial insulin therapy (HbA1c &gt;6.5%)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
            <count group_id="B2" value="128"/>
            <count group_id="B3" value="130"/>
            <count group_id="B4" value="386"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="9.57"/>
                    <measurement group_id="B2" value="54.7" spread="10.14"/>
                    <measurement group_id="B3" value="54.6" spread="9.41"/>
                    <measurement group_id="B4" value="55.2" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>USA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="6.41"/>
                    <measurement group_id="B2" value="34.3" spread="6.57"/>
                    <measurement group_id="B3" value="34.5" spread="7.04"/>
                    <measurement group_id="B4" value="34.0" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" spread="6.95"/>
                    <measurement group_id="B2" value="9.7" spread="5.68"/>
                    <measurement group_id="B3" value="10.5" spread="6.00"/>
                    <measurement group_id="B4" value="10.2" spread="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.1" spread="21.46"/>
                    <measurement group_id="B2" value="99.6" spread="20.22"/>
                    <measurement group_id="B3" value="101.2" spread="24.98"/>
                    <measurement group_id="B4" value="99.6" spread="22.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hemoglobin A1c (HbA1c) From Baseline to Week 12</title>
        <time_frame>12 weeks from Baseline</time_frame>
        <population>Safety Population (excluding patients from Good Clinical Practice [GCP] non-compliant sites)</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine + Sulfonylurea (SU) + Thiazolidinedione (TZD)</title>
            <description>Arm 1: Insulin glargine (IG) administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine + Metformin (MET) + Thiazolidinedione (TZD)</title>
            <description>Arm 2: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine + Metformin (MET) + Sulfonylurea (SU)</title>
            <description>Arm 3: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c (HbA1c) From Baseline to Week 12</title>
          <population>Safety Population (excluding patients from Good Clinical Practice [GCP] non-compliant sites)</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.72"/>
                    <measurement group_id="O2" value="-1.2" spread="1.35"/>
                    <measurement group_id="O3" value="-1.2" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Individual Time Points in HbA1c, Insulin Doses, and Total Insulin Dosage</title>
        <time_frame>60 weeks from Baseline</time_frame>
        <population>The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine + Sulfonylurea (SU) + Thiazolidinedione (TZD)</title>
            <description>Arm 1: Insulin glargine (IG) administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine + Metformin (MET) + Thiazolidinedione (TZD)</title>
            <description>Arm 2: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine + Metformin (MET) + Sulfonylurea (SU)</title>
            <description>Arm 3: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Individual Time Points in HbA1c, Insulin Doses, and Total Insulin Dosage</title>
          <population>The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving an HbA1C Less Than (&lt;) 7.0% and Less Than (&lt;) 6.5%</title>
        <time_frame>60 weeks from Baseline</time_frame>
        <population>The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine + Sulfonylurea (SU) + Thiazolidinedione (TZD)</title>
            <description>Arm 1: Insulin glargine (IG) administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine + Metformin (MET) + Thiazolidinedione (TZD)</title>
            <description>Arm 2: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine + Metformin (MET) + Sulfonylurea (SU)</title>
            <description>Arm 3: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving an HbA1C Less Than (&lt;) 7.0% and Less Than (&lt;) 6.5%</title>
          <population>The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Study Time Points in 7-point Blood Glucose (BG) Profile (Before Meals, 2 Hours After Meals, at Bedtime)</title>
        <time_frame>60 weeks from Baseline</time_frame>
        <population>The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine + Sulfonylurea (SU) + Thiazolidinedione (TZD)</title>
            <description>Arm 1: Insulin glargine (IG) administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine + Metformin (MET) + Thiazolidinedione (TZD)</title>
            <description>Arm 2: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine + Metformin (MET) + Sulfonylurea (SU)</title>
            <description>Arm 3: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Study Time Points in 7-point Blood Glucose (BG) Profile (Before Meals, 2 Hours After Meals, at Bedtime)</title>
          <population>The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Study and to Individual Time Points in Components of Lipid Profile (Total Cholesterol, High-density Lipoprotein Cholesterol [HDL], Low-density Lipoprotein Cholesterol [LDL], Triglycerides, LDL Subfractions)</title>
        <time_frame>60 weeks from Baseline</time_frame>
        <population>The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine + Sulfonylurea (SU) + Thiazolidinedione (TZD)</title>
            <description>Arm 1: Insulin glargine (IG) administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine + Metformin (MET) + Thiazolidinedione (TZD)</title>
            <description>Arm 2: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine + Metformin (MET) + Sulfonylurea (SU)</title>
            <description>Arm 3: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Study and to Individual Time Points in Components of Lipid Profile (Total Cholesterol, High-density Lipoprotein Cholesterol [HDL], Low-density Lipoprotein Cholesterol [LDL], Triglycerides, LDL Subfractions)</title>
          <population>The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrences of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia, and Serious Hypoglycemia</title>
        <description>Symptomatic hypoglycemia (BG&lt;70 mg/dL, BG&lt;50 mg/dL): including 1 or more symptoms: headache, dizziness, general feeling of weakness, drowsiness, confusion, pallor, irritability, trembling, sweating, rapid heartbeat &amp; a cold, clammy feeling.
Mild–to-moderate hypoglycemia: SMBG ≥ 36 mg/dL but &lt;70 mg/dL
Severe hypoglycemia: assistance of another party is required &amp; either:
SMBG of &lt;36 mg/dL, or
with prompt response to treatment with oral carbohydrates, IV glucose or glucagon.
Serious hypoglycemia:
Hypoglycemia with coma/loss of consciousness Or Hypoglycemia seizure/convulsion.</description>
        <time_frame>60 weeks from Baseline</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine + Sulfonylurea (SU) + Thiazolidinedione (TZD)</title>
            <description>Arm 1: Insulin glargine (IG) administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine + Metformin (MET) + Thiazolidinedione (TZD)</title>
            <description>Arm 2: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine + Metformin (MET) + Sulfonylurea (SU)</title>
            <description>Arm 3: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrences of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia, and Serious Hypoglycemia</title>
          <description>Symptomatic hypoglycemia (BG&lt;70 mg/dL, BG&lt;50 mg/dL): including 1 or more symptoms: headache, dizziness, general feeling of weakness, drowsiness, confusion, pallor, irritability, trembling, sweating, rapid heartbeat &amp; a cold, clammy feeling.
Mild–to-moderate hypoglycemia: SMBG ≥ 36 mg/dL but &lt;70 mg/dL
Severe hypoglycemia: assistance of another party is required &amp; either:
SMBG of &lt;36 mg/dL, or
with prompt response to treatment with oral carbohydrates, IV glucose or glucagon.
Serious hypoglycemia:
Hypoglycemia with coma/loss of consciousness Or Hypoglycemia seizure/convulsion.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any reported symptomatic Hypoglycemic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptomatic events with Self-monitored BG (SMBG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG &lt;70 mg/dL with symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG &lt;50mg/dL with symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMBG &lt;36 mg/dL with symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Hypoglycemias</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe only due to SMBG &lt;36mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe: Prompt response to CHO countermeasure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe:SMBG&lt;36mg/dL, prompt response to CHO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coma/Loss of Consciousness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia and Serious Hypoglycemia</title>
        <description>Symptomatic hypoglycemia (BG&lt;70 mg/dL, BG&lt;50 mg/dL): including 1 or more symptoms: headache, dizziness, general feeling of weakness, drowsiness, confusion, pallor, irritability, trembling, sweating, rapid heartbeat &amp; a cold, clammy feeling.
Mild–to-moderate hypoglycemia: SMBG ≥ 36 mg/dL but &lt;70 mg/dL
Severe hypoglycemia: assistance of another party is required &amp; either:
SMBG of &lt;36 mg/dL, or
with prompt response to treatment with oral carbohydrates, IV glucose or glucagon.
Serious hypoglycemia:
Hypoglycemia with coma/loss of consciousness Or Hypoglycemia seizure/convulsion.</description>
        <time_frame>60 Weeks from Baseline</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Glargine + Sulfonylurea (SU) + Thiazolidinedione (TZD)</title>
            <description>Arm 1: Insulin glargine (IG) administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O2">
            <title>Insulin Glargine + Metformin (MET) + Thiazolidinedione (TZD)</title>
            <description>Arm 2: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
          <group group_id="O3">
            <title>Insulin Glargine + Metformin (MET) + Sulfonylurea (SU)</title>
            <description>Arm 3: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Hypoglycemia, Symptomatic Hypoglycemia, Severe Hypoglycemia and Serious Hypoglycemia</title>
          <description>Symptomatic hypoglycemia (BG&lt;70 mg/dL, BG&lt;50 mg/dL): including 1 or more symptoms: headache, dizziness, general feeling of weakness, drowsiness, confusion, pallor, irritability, trembling, sweating, rapid heartbeat &amp; a cold, clammy feeling.
Mild–to-moderate hypoglycemia: SMBG ≥ 36 mg/dL but &lt;70 mg/dL
Severe hypoglycemia: assistance of another party is required &amp; either:
SMBG of &lt;36 mg/dL, or
with prompt response to treatment with oral carbohydrates, IV glucose or glucagon.
Serious hypoglycemia:
Hypoglycemia with coma/loss of consciousness Or Hypoglycemia seizure/convulsion.</description>
          <population>Safety Population</population>
          <units>events/ patient-year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Exposure (Patient-years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.941" spread="0.3285"/>
                    <measurement group_id="O2" value="0.943" spread="0.3692"/>
                    <measurement group_id="O3" value="0.967" spread="0.3118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemic (HE) event with SMBG &lt;70mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="35.54"/>
                    <measurement group_id="O2" value="16.5" spread="20.35"/>
                    <measurement group_id="O3" value="25.3" spread="26.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HE with SMBG &lt;50mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="7.48"/>
                    <measurement group_id="O2" value="3.3" spread="5.74"/>
                    <measurement group_id="O3" value="5.6" spread="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HE with SMBG &lt;36mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.87"/>
                    <measurement group_id="O2" value="0.3" spread="0.76"/>
                    <measurement group_id="O3" value="0.6" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe HE (BG&lt;36mg/dL or prompt response to CHO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.31"/>
                    <measurement group_id="O2" value="0.1" spread="0.53"/>
                    <measurement group_id="O3" value="0.1" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious HE (coma/loss of consciousness,seizure)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.14"/>
                    <measurement group_id="O2" value="0.0" spread="0.09"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Insulin Glargine + Sulfonylurea (SU) + Thiazolidinedione (TZD)</title>
          <description>Arm 1: Insulin glargine (IG) administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
        </group>
        <group group_id="E2">
          <title>Insulin Glargine + Metformin (MET) + Thiazolidinedione (TZD)</title>
          <description>Arm 2: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
        </group>
        <group group_id="E3">
          <title>Insulin Glargine + Metformin (MET) + Sulfonylurea (SU)</title>
          <description>Arm 3: Insulin glargine (IG) administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c &gt;6.5%)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Bone cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Affairs study director</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>publicregistryUSMA@sanofi-aventis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

